Using a PEL xenograft mouse model, we found that NEK2 inhibition significantly prolongs host survival and decreases PEL burden as measured by ascites volume, tumor weight, and in vivo imaging, with no detectable liver toxicity. Here, NEK2 is linked to neoplasm.